Litigation Details for UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
✉ Email this page to a colleague
UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-03-05 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Referred To | ||
| Patents | 10,130,589; 6,884,434 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UCB, Inc. v. Actavis Laboratories UT, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-09-16 | 135 | Opinion - Memorandum Opinion | claims of U.S. Patent No. 10,130,589 (the "'589 Patent"), the patent asserted by the…parties regarding related patents, U.S. Patent Nos. 6,884,434 (the "'434 Patent") and 8,232,…quot;'414 Patent"), and held the '414 Patent invalid and the '434 Patent valid and infringed…Orange Book patents related to Neupro® to determine whether any of them were 'blocking patents[,]"…and fourth, UCB's other patents did not function as blocking patents. (D.I. 110 at 4-5.) | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
